Logo image of VTVT

VTV THERAPEUTICS INC- CL A (VTVT) Stock Price, Forecast & Analysis

USA - NASDAQ:VTVT - US9183852048 - Common Stock

20.7 USD
-0.37 (-1.76%)
Last: 10/31/2025, 10:55:19 AM

VTVT Key Statistics, Chart & Performance

Key Statistics
Market Cap66.03M
Revenue(TTM)17.00K
Net Income(TTM)-19555000
Shares3.19M
Float1.69M
52 Week High26.99
52 Week Low12.62
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.12
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO2015-07-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


VTVT short term performance overview.The bars show the price performance of VTVT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30 40

VTVT long term performance overview.The bars show the price performance of VTVT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of VTVT is 20.7 USD. In the past month the price decreased by -12.21%. In the past year, price increased by 50.18%.

VTV THERAPEUTICS INC- CL A / VTVT Daily stock chart

VTVT Latest News, Press Relases and Analysis

VTVT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.73 387.90B
AMGN AMGEN INC 13.54 158.92B
GILD GILEAD SCIENCES INC 14.55 147.85B
VRTX VERTEX PHARMACEUTICALS INC 24.96 108.42B
REGN REGENERON PHARMACEUTICALS 14.58 69.58B
ALNY ALNYLAM PHARMACEUTICALS INC 345.95 58.95B
ARGX ARGENX SE - ADR 61.68 50.32B
INSM INSMED INC N/A 41.13B
ONC BEONE MEDICINES LTD-ADR 4.99 33.95B
NTRA NATERA INC N/A 27.14B
BNTX BIONTECH SE-ADR N/A 24.76B
BIIB BIOGEN INC 9.14 22.43B

About VTVT

Company Profile

VTVT logo image vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Company Info

VTV THERAPEUTICS INC- CL A

3980 Premier Dr, Suite 310

High Point NORTH CAROLINA 27265 US

CEO: Stephen L. Holcombe

Employees: 23

VTVT Company Website

VTVT Investor Relations

Phone: 13368410300

VTV THERAPEUTICS INC- CL A / VTVT FAQ

What does VTVT do?

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.


What is the stock price of VTV THERAPEUTICS INC- CL A today?

The current stock price of VTVT is 20.7 USD. The price decreased by -1.76% in the last trading session.


What is the dividend status of VTV THERAPEUTICS INC- CL A?

VTVT does not pay a dividend.


What is the ChartMill technical and fundamental rating of VTVT stock?

VTVT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists VTVT stock?

VTVT stock is listed on the Nasdaq exchange.


Is VTV THERAPEUTICS INC- CL A (VTVT) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTVT.


What is the expected growth for VTVT stock?

The Revenue of VTV THERAPEUTICS INC- CL A (VTVT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


VTVT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to VTVT. When comparing the yearly performance of all stocks, VTVT is one of the better performing stocks in the market, outperforming 90.8% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VTVT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VTVT. VTVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VTVT Financial Highlights

Over the last trailing twelve months VTVT reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS increased by 13.93% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -73.94%
ROE -708%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-13.48%
Sales Q2Q%N/A
EPS 1Y (TTM)13.93%
Revenue 1Y (TTM)-98.3%

VTVT Forecast & Estimates

8 analysts have analysed VTVT and the average price target is 36.21 USD. This implies a price increase of 74.93% is expected in the next year compared to the current price of 20.7.

For the next year, analysts expect an EPS growth of 0.14% and a revenue growth -100% for VTVT


Analysts
Analysts82.5
Price Target36.21 (74.93%)
EPS Next Y0.14%
Revenue Next Year-100%

VTVT Ownership

Ownership
Inst Owners39.63%
Ins Owners0.63%
Short Float %1.35%
Short Ratio5.47